医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Ulcerative Colitis (Event Driven)

2012年09月26日 AM02:07
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/9kvfqr/ulcerative) has announced the addition of Decision Resources, Inc’s new report “Ulcerative Colitis (Event Driven)” to their offering.

Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for additional pharmacotherapies that more effectively treat moderate to severe disease and maintain disease remission better than do existing drugs. The increasing use of tumor necrosis factor-alpha (TNF-a) inhibitors and the uptake of two emerging therapies with a novel mechanism of action among patients with moderate to severe disease will drive strong growth of the UC market throughout our 2010-2020 forecast period, while innovative reformulations of current therapies will expand treatment options for patients with mild to moderate UC.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– 6 Market Outlook

– Appendix A BibliographyUlcerative Colitis

– Appendix B Market Forecast Methodology

– Appendix C Experts InterviewedUlcerative Colitis

– Appendix D Supplemental Epidemiology Bibliography

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/9kvfqr/ulcerative

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Kyoto Semiconductor Announces a Photodiode in the Industry’s Smallest Class, with a Broad Range of Sensitivity Wavelengths, from 400 to 1,700 nm
  • 希少な重篤肺がんと診断された患者に対するファーストライン治療としての武田薬品のALUNBRIG®(ブリガチニブ)を米国FDAが承認
  • 美国FDA核准武田ALUNBRIG® (brigatinib)用作一种罕见严重类型肺癌患者的一线治疗选择
  • Firetinas: Is Your Telethermographic Scanner Accurate to Screen COVID-19?
  • U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer